Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington’s disease

Currently, there are no therapies available to modify the disease progression of Huntington’s disease (HD). Recent clinical trial failures of antisense oligonucleotide candidates in HD have demonstrated the need for new therapeutic approaches. Here, we developed a novel in-silico fragment scanning a...

Descripción completa

Detalles Bibliográficos
Autores principales: Galyan, Simon Marius, Ewald, Collin Y., Jalencas, Xavier, Masrani, Shyam, Meral, Selin, Mestres, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668931/
https://www.ncbi.nlm.nih.gov/pubmed/36385140
http://dx.doi.org/10.1038/s41598-022-21900-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668931/
https://www.ncbi.nlm.nih.gov/pubmed/36385140
http://dx.doi.org/10.1038/s41598-022-21900-2

Ejemplares similares